STOCK MARKET BSE NSE

COVID-19: Centre approves emergency use of anti-viral drug 'Favipiravir' 

Favipiravir manufactured by Glenmark in India is a generic version of the Japanese flu drug Avigan by Fujifilm Toyama Chemical, a subsidiary of Fujifilm Corporation.

Published: 19th June 2020 10:54 PM  |   Last Updated: 20th June 2020 08:12 AM   |  A+A-

Doctors at a private clinic attend to patients in makeshift swab-collection booths | VINAY MADAPU

Doctors at a private clinic attend to patients in makeshift swab-collection booths | VINAY MADAPU

By Express News Service

NEW DELHI: India’s drug regulator has approved an oral antiviral- favipiravir- for restricted emergency use for COVID-19 patient in India on Friday as the evidence has emerged that it prevents mild and moderate disease from progressing further and reduces viral load within 4-5 days.

Favipiravir manufactured by Glenmark in India is a generic version of the Japanese flu drug Avigan by Fujifilm Toyama Chemical, a subsidiary of Fujifilm Corporation.

The Drug Controller General of India has approved phase 3 trials of the drug in the country after trials in 10 hospitals with 150 patients showed that a short course of this oral antiviral appears to prevent mild and moderate from progressing to severe and cuts viral load within four to five days. 

Sources said that in March, Glenmark decided to take a gamble -- on the basis of observations on Covid-19 research in China and Japan -- and decided to start making a generic version of favipiravir after which it conducted clinical trials in 10 hospitals in May and June.

A statement by the company on Friday said: "Glenmark has successfully developed the API and the formulations for the product through its in-house R&D team. Favipiravir has demonstrated activity against influenza viruses and has been approved in Japan for the treatment of novel influenza virus infections. The molecule, if commercialized, will be marketed under the brand name FabiFlu in India."

Monika Tandon, vice president and head, clinical development of the pharma company said: "Several health and medical experts, both in and outside of Glenmark are eager to see the effect that Favipiravir has on COVID-19 cases. We believe the study results will be significant as there is currently no effective treatment for the virus."

She added, "The data we get from these trials will point us in a clearer direction with regard to Covid-19 treatment and management."

Stay up to date on all the latest Nation news with The New Indian Express App. Download now

Comments

Disclaimer : We respect your thoughts and views! But we need to be judicious while moderating your comments. All the comments will be moderated by the newindianexpress.com editorial. Abstain from posting comments that are obscene, defamatory or inflammatory, and do not indulge in personal attacks. Try to avoid outside hyperlinks inside the comment. Help us delete comments that do not follow these guidelines.

The views expressed in comments published on newindianexpress.com are those of the comment writers alone. They do not represent the views or opinions of newindianexpress.com or its staff, nor do they represent the views or opinions of The New Indian Express Group, or any entity of, or affiliated with, The New Indian Express Group. newindianexpress.com reserves the right to take any or all comments down at any time.

flipboard facebook twitter whatsapp